Latest Breaking News On - High unmet medical needs - Page 1 : vimarsana.com

Clinical Data Abstract Presentation; IP Portfolio of 9 Patents; Phase 3 Cancer Treatments: RenovoRx NASDAQ: RNXT $RNXT

Clinical Data Abstract Presentation; IP Portfolio of 9 Patents; Phase 3 Cancer Treatments: RenovoRx NASDAQ: RNXT $RNXT
einnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from einnews.com Daily Mail and Mail on Sunday newspapers.

United statesSalt lake cityFrance generalMichaelj pishvaianShaun bagaiGustave roussyFrontpagestocks corporateadsShripal gandhiMichel ducreuxResearch supports renovorx lead oncology productRenovorx incImugene ltdMiami cancer instituteUniversity of paris sudData monitoring committeeGastrointestinal tract cancer group

Biopharma Company Issues New Patent Application; Phase 3 Clinical Trials for Cancer Treatments: RenovoRx (NASDAQ: RNXT)

Biopharma Company Issues New Patent Application; Phase 3 Clinical Trials for Cancer Treatments: RenovoRx (NASDAQ: RNXT)
einnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from einnews.com Daily Mail and Mail on Sunday newspapers.

United statesFrance generalMichaelj pishvaianFrontpagestocks corporateadsShripal gandhiMichel ducreuxGustave roussyRenovorx incSaclay universityEuropean organisation for researchClinical trials in partnershipImugene ltdGastrointestinal tract cancer groupCompany scientific advisory boardMiami cancer instituteSchool of medicine

Adaptimmune Therapeutics PLC: Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors

- 44% Objective Response Rate (ORR) with a single dose of ADP-A2M4CD8 in 25 heavily pre-treated patients with late-stage ovarian, urothelial, and head & neck cancers Further clinical development planned

United kingdomSri lankaUnited statesSchleswig holsteinKathleen mooreDavid hongAdrian rawcliffeJulip millerDana lynchInvestigator councilNational cancer institute surveillanceEnd results programStephenson cancer centerUniversity of oklahomaInternational agency for research on cancerDepartment of investigational cancer therapeutics